Our Mission
Facilitate a new diagnostic paradigm in the field of osteoarthritis, where the presence, progression, and treatment efficacy can be observed and assessed in real-time
We work collaboratively with innovators driving progress for the betterment of patient care and disease treatment worldwide.
Our Story
In the early 2020s, a visionary team of seasoned professionals, led by Thomas J. Meade, embarked on a transformative journey with the creation of PreDx, a company dedicated to revolutionizing the imaging of osteoarthritis.
By developing unique bio-responsive contrast agents (BCAs), PreDx's technology allows for the real-time, non-invasive monitoring of senescent cells in osteoarthritic joints, a breakthrough of significant importance that stands alone in its capacity to make visible the previously unseen.
The concept is simple but elegant: BCAs can detect senescent cells, triggering a measurable change in contrast on MR images. They are capable of visualizing the physiological changes associated with osteoarthritis, offering valuable insights into the distribution and activity levels of senescent cells, something that was previously unattainable by non-invasive means.
Thomas J. Meade (Founder) is a distinguished professor at Northwestern University across multiple disciplines, has made a significant impact in the field of biotechnology, founding five innovative companies focused on revolutionary medical diagnostics and treatments. His entrepreneurial prowess is exemplified by the success of Clinical MicroSensors, which was sold to Roche in 2021 for $1.8 billion, demonstrating the immense value of his pioneering work.
Kurt Zoller (CEO) is a prominent leader in the health sector, utilizing his expertise in marketing and communications to create impactful campaigns, notably managing a $10 million budget at Northwestern Medicine and fostering growth of over 150% at Epsilon Healthcare. His accomplishments extend beyond the corporate world, as he's demonstrated commitment to community service as president of the Wilmette Rotary Club and marketing committee leader for Prevent Blindness, reinforcing his multifaceted influence in healthcare and beyond.
Experienced Leadership
Meet the Team
Founder
Thomas Meade
Specializes in advanced molecular imaging, holding positions across four departments and founding five biotech companies, including Clinical Micro Sensors which sold for $1.8 billion in 2021. With over 275 papers and 107 issued US patents, his startups have pioneered in areas like DNA detection, cancer imaging, and environmental pollutant sequestration.
CEO
Kurt Zoller
Directed Northwestern Medicine's hospital marketing and spearheaded growth at Epsilon Healthcare, increasing business by over 150% in two years. As the founder of NPD Marketing Partners, he played a pivotal role in attracting premier clients like AbbVie, and has dedicated 13 years serving on the board of Prevent Blindness as the marketing committee leader.
Director
Dr. Gary Blackburn
Dr. Gary Blackburn is the founder of BioMeDx Advisors and has played pivotal roles at companies like Islet Sciences, DxTerity Diagnostics, and Claremont BioSolutions. With a Ph.D. in Bioengineering and over 70 patents to his name, he has been instrumental in development pharmaceutical and diagnostic technologies.
Secretary
Christopher Meade
Chris is a business leader, merging expertise in data analytics and healthcare education with a proven track record in -strategy and technological innovation, as demonstrated by his successful career at Oracle NetSuite and his co-founding of Podcasts Abbreviated, a digestible content-focused media company.